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Abstract  1 
Background 2 
Observational studies suggest an association between reduced lung function and risk of 3 
coronary artery disease and ischaemic stroke, independent of shared cardiovascular risk 4 
factors such as cigarette smoking. We use the latest genetic epidemiological methods to 5 
determine if impaired lung function is causally associated with an increased risk of 6 
cardiovascular disease. 7 
Methods and Findings 8 
Mendelian Randomization uses genetic variants as instrumental variables to investigate 9 
causation. Preliminary analysis used two sample Mendelian Randomization with lung 10 
function single nucleotide polymorphisms shown to confer a high risk of COPD. To avoid 11 
collider bias the main analysis used single nucleotide polymorphisms for lung function 12 
identified from UKBiobank in a Multivariable Mendelian Randomization model conditioning 13 
for height, body mass index and smoking.  14 
Multivariable Mendelian Randomization shows strong evidence that reduced FVC causes 15 
increased risk of coronary artery disease, Odds Ratio:1·32 (1·19-1·46) per Standard 16 
Deviation. Reduced FEV1 is unlikely to be cause increased risk of coronary artery disease as 17 
evidence of its effect becomes weak after conditioning for height 1·08 (0·89, 1·30). There is 18 
weak evidence that reduced lung function increases risk of ischaemic stroke. 19 
Conclusion 20 
There is strong evidence that reduced FVC is independently and causally associated with 21 
coronary artery disease. Although the mechanism remains unclear, FVC could be taken into 22 
consideration when assessing cardiovascular risk and considered a potential target for 23 
reducing cardiovascular events. FEV1 and airflow obstruction do not appear to cause 24 
increased cardiovascular events, confounding and collider bias may explain previous findings 25 
of a causal association.  26 
Word Count abstract: 245 27 




Introduction  29 
 30 
Multi-morbidity, the co-existence of multiple diseases in an individual, is associated with 31 
poor quality of life, mortality and polypharmacy.[1] Impaired lung function measures such as 32 
Forced Expiratory Volume in one second (FEV1) and Forced Expiratory Volume (FVC) have 33 
been found to be strongly associated with multi-morbidity and are reported as independent 34 
predictors of cardiovascular disease.[2] Although research has often focused on the 35 
contribution of FEV1 and obstructive airways disease to cardiovascular risk, FVC has been 36 
shown to be a stronger predictor of survival, and appears to add value to the Framingham 37 
Risk Score for prediction of mortality.[3, 4] However, it is unclear if there is a causal link 38 
between lung function and multi-morbidity or if the association is due to confounding factors 39 
such as cigarette smoking.  40 
 41 
Observational studies have reported that Chronic Obstructive Pulmonary Disease (COPD), 42 
decreased FEV1, FVC and FEV1/FVC ratio are all associated with an increased the risk of 43 
coronary artery disease.[5, 6] However results are inconsistent, with some studies reporting no 44 
association,[7] or that the association is limited to those with abnormally high blood 45 
pressure.[8] There is also evidence suggesting that COPD and impaired lung function are  46 
associated with an increased risk of stroke.[9]  47 
 48 
Impaired lung function and associated lung diseases could have a direct detrimental effect on 49 
cardiovascular health via a number of biological pathways including systemic inflammation 50 
or oxidative stress.[10, 11] However the mechanisms may vary between different lung 51 





Mendelian Randomization (MR) is a method which can overcome problems of unmeasured 54 
confounding and reverse causation typical of conventional observational epidemiology.[13] 55 
MR allows causal inference through the use of genetic variants as proxies for modifiable risk 56 
factors or health outcomes.[14] MR uses genetic data, e.g. single nucleotide polymorphisms 57 
(SNPs) that are associated with an exposure (in this case lung function), as instrumental 58 
variables (IV) to assess the causal effect of the exposure on the outcome of interest (in this 59 
case cardiovascular disease ).[15]  60 
 61 
MR has multiple advantages, it uses genetic variants which are randomly allocated at 62 
conception so they can be exploited to simulate randomisation.[15] Genetic variants are not 63 
influenced by behavioural or environmental factors and are far less susceptible to bias from 64 
reverse causation. Additionally, the effects are equivalent to lifetime differences, reducing 65 
issues relating to transient fluctuations in exposures.[16] Multivariable MR (MVMR) has 66 
further advantages, it includes multiple exposures in the model allowing estimation of the 67 
direct causal effect of each exposure on the outcome. Each exposure SNP has its effect on all 68 
exposures e.g. lung function (LF) trait and height included in the MR model allowing for 69 
conditioning. MVMR is a robust method when using two exposures that could act as a 70 
confounder, mediator or collider of the exposure-outcome relationship.[17, 18] Our objective 71 
was to determine if impaired lung function causally increases the risk of cardiovascular 72 
disease. 73 
Methods  74 
 75 
Exposures – Shrine et al preliminary analysis [19] 76 
 77 
We used data from the largest currently available lung function GWAS, by Shrine et al to 78 




GWAS reported 279 genome wide significant SNPs (p<5×10−9) in European ancestry 80 
population and was adjusted for age, age2, height, smoking status. Full details are provided 81 
elsewhere.[19] 82 
 83 
Given that the Shrine et al GWAS adjusted for covariates of lung function and cardiovascular 84 
disease e.g. height and smoking, this can lead to collider bias as SNPs can be related to both 85 
the covariates e.g. height and to other adverse risk factors.[16]  This can lead to false positive 86 
SNP discoveries and bias (towards null effect) in MR studies.[20]  87 
Exposures – Main analysis MVMR 88 
To avoid the collider bias we used exposure SNPs discovered in GWAS that had not been 89 
adjusted for covariates in an MVMR model. To find suitable exposure SNPs we used the 90 
UKBiobank, of 502,543 individuals aged between 40 and 69 at recruitment across the UK.[21] 91 
Participants completed detailed health questionnaires and blood samples were taken for 92 
genotyping. Of these 353,315 participants have “best measures” of pre-bronchodilator FEV1 93 
and FVC, measured as absolute values in litres. We performed a GWAS on these individuals 94 
(adjusting for sex). We also performed a GWAS based on 55,907 cases of airflow obstruction 95 
(defined as FEV1/FVC <0·70) and 297,408 controls (FEV1/FVC ≥0·70). The SNPs discovered 96 
in this unadjusted GWAS were then used in a two-sample MVMR model conditioning with 97 
SNPs for covariates of exposure and outcome: standing height, body mass index (BMI) and 98 
current smoking. SNPs for these covariates were identified in pre-existing GWAS performed 99 
in the UKBiobank.[22] See online supplement for details. NB. Genetic variants function is 100 
independent of age and adjusting for it in a two sample MR model is not necessary or possible 101 
(as age is not genetically determined). All exposure SNPs were discovered in only European 102 






We used CARDIOGRAMplusC4D GWAS based on 60,901 cases of coronary artery disease 106 
and 123,504 controls, 77% of whom were of European ancestry.[23] Coronary artery disease 107 
was defined by myocardial infarction, acute coronary syndrome, chronic stable angina or 108 
coronary stenosis of >50%. 109 
For stroke we used MEGASTROKE GWAS based on 34,217 cases of acute ischaemic stroke 110 
and 406,111 controls, all of European ancestry.[24]  There was no overlap between our 111 
exposure and outcome population samples. 112 
Statistical Analysis 113 
 114 
Statistical analysis was done using R Studio version 3.6.1 with MRCIEU/TwoSampleMR and 115 
MRInstruments packages.[17, 25]  116 
F-statistics were calculated to assess exposure instruments strength.[26] Linkage 117 
disequilibrium clumping (LD-clumping) and Steiger filtering were performed.[25] Duplicate 118 
SNPs and palindromic SNPs were removed, and all SNPs were harmonised. Proxies were 119 
identified when CAD was the outcome. See appendix 3 for more details. 120 
 121 
Main Mendelian Randomization Analysis 122 
 123 
Inverse Variance Weighting (IVW) was used for main effect estimate for both MVMR and 124 
2S-MR analyses. This IVW is a weighted regression of SNP-outcome on SNP-exposure 125 





Results  128 
Shrine et al preliminary analysis 129 
Due to collider bias, results from this analysis should be interpreted with caution. When 130 
adjusting for a covariate the effect estimate of the SNP with lung function will be biased 131 
by the correlation between the covariate and lung function multiplied by their 132 
association with covariate. For example, if a SNP has a strong positive effect on height it 133 
would reduce the observed effect on lung function. Adjusting for a covariate in a GWAS 134 
could induce an association between SNPs associated with the covariate and the 135 
adjusted trait that is inverse to the true association between each SNP and the 136 
covariate.[20] This bias in the SNP-exposure association will feed through to any MR 137 
estimates obtained using it and could lead to bias in the MR estimates obtained, either 138 
towards or away from the null. The implications for MR estimates from covariate 139 
adjusted GWAS are explained in detail elsewhere. [27]. Please see appendix 8 for 140 
directed acyclic graph and further detail. 141 
All analysis showed weak evidence of an effect, variable direction of effect and wide 142 
confidence intervals. These results are reported in further detail in the supplementary 143 
information. We proceeded with MVMR as our main analysis as a more robust method able 144 
to account for collider bias.  145 
MVMR 146 
Using a threshold of p<5×10-8, after quality control and LD-clumping the unadjusted GWAS 147 
of lung function in UKBiobank produced 360 SNPs for FEV1, 464 SNPs for FVC and 154 148 
SNPs for FEV1/FVC <0·70 explaining 3·6%, 4·8% and 0·9% of variance respectively. F-149 
statistic for FEV1 = 38, FVC = 40 and Ratio <0.7 = 36. For covariates, F-statistic for standing 150 






MVMR analysis – FEV1 and FVC as exposure, CAD as outcome 154 
Results are presented as per SD decrease in lung function trait. Analysis showed strong 155 
evidence of an increased risk of CAD per SD decrease in FVC (OR:1·32 per SD; 95% CI: 156 
1·19-1·46) as shown in Table 1. This effect did not attenuate after conditioning for BMI 157 
(1.41; 1·25-1·59) or current smoking (1·32; 1·19-1·47) but was weaker after conditioning for 158 
height (OR: 1·22; 1·03-1·44). 159 
 160 
Table 1. Multivariable MR results of FEV1 and FVC on Coronary Artery Disease and 161 













OR (95% CI)* for 
Ischaemic Stroke 
FEV1 Nil 300/Nil 1·27 (1·12, 1·44) 291/Nil 1·11 (0·97-1·26) 
FEV1 Height 194/744 1·08 (0·89, 1·30) 193/741 1.01 (0·83, 1·22) 
FEV1 BMI 179/645 1·26 (1·08, 1·47) 185/660 1·03 (0·88, 1·20) 
FEV1 Smoking 274/15 1·26 (1·10, 1·44) 273/12 1·11 (0·95, 1·29) 
FVC Nil 391/Nil 1·32 (1·19-1·46) 384/Nil 1·12 (1·01-1·24) 
FVC Height  272/726 1·22 (1·03, 1·44) 273/728 1·04 (0·88, 1·24) 
FVC BMI 227/599 1·41 (1·25, 1·59) 227/607 1·05 (0·93, 1·19) 
FVC Smoking 359/15 1·32 (1·19, 1·47) 368/11 1·11 (1·00, 1·23) 
*per SD decrease in lung function trait 164 
OR – Odds Ratio. 95% CI – 95% Confidence Interval. LF – Lung Function 165 
 166 
There is strongPrior to any conditioning, there was evidence that reduced FEV1 increases risk 167 
of CAD (OR: 1·27 per SD; 95% CI: 1·12-1·44). However, when conditioning for height the 168 




1·30) Table 1. This is probably due to the pleiotropy in the MR analysis as the unadjusted 170 
GWAS would have discovered SNPs that affected LF via height. Therefore, there is limited 171 
evidence of a direct effect of FEV1 on cardiovascular risk. Conditioning for BMI (1·26; 1·08-172 
1·47) and current smoking (1·26; 1·10-1·44) made minimal difference to the estimated effect. 173 
 174 
MVMR analysis – FEV1 and FVC as exposure, ischaemic stroke as outcome 175 
There is little evidence to suggest that reduced FEV1 increases the risk of ischaemic stroke 176 
(OR: 1·11 per SD; 95% CI: 0·97-1·26) Table 1. The magnitude decreased further when 177 
conditioning for both height and BMI, although the direction remained consistent. There is 178 
evidence that a decrease in FVC increases risk of ischaemic stroke (1·23; 1·01-1·24) but the 179 
effect size and strength of evidence attenuates after conditioning for height or BMI (1·16; 180 
0·98-1·38 and 1·05; 0·93-1·19 respectively). Results for effects of FEV1 and FVC on CAD 181 
and ischaemic stroke after conditioning for all covariates together are in supplementary 182 
information appendix 4. 183 
 184 
MVMR analysis – FEV1/FVC ratio <0.7 as exposure, CAD and ischaemic stroke as outcomes 185 
Steiger filtering removed 87 SNPs for FEV1/FVC ratio <0·7 with CAD as the outcome and 96 186 
SNPs with ischaemic stroke as the outcome. We found very little evidence of an effect of 187 
liability to airflow obstruction on CVD as can be seen in Table 2. These results may be due to 188 
weak instruments, or they could be supporting the evidence that reduced FVC has more of an 189 





Table 2. Multivariable MR results of and FEV1/FVC <0·7 on Coronary Artery Disease and 192 
Ischaemic Stroke using UKBiobank lung function GWAS  193 
*per SD increase in liability to ratio <0·7194 
 195 
 196 
Discussion  197 
 198 
This MVMR study provides evidence that a one standard deviation reduction in FVC causes 199 
approximately a 20% increased risk of CAD. This finding confirms causality of previous 200 
observational associations.[5, 6] These results are unlikely to be affected by reverse causation 201 
or confounding factors due to the use of SNPs as instrumental variables. This effect was not 202 
seen in the preliminary non-MVMR analysis because of collider bias introduced to the model 203 
by covariate adjustment in the Shrine et al discovery GWAS. Our main analysis used MVMR 204 
which is a robust tool when a secondary exposure acts as a confounder, a mediator, a 205 
pleiotropic pathway and a collider.[28]  206 
Although historically, most observational studies of cardiovascular morbidity have focused on 207 
FEV1 and COPD, we found little evidence of a causal association between FEV1 and liability 208 
to obstructive ratio on CVD risk. These results mirror findings that FVC is stronger predictor 209 
of overall survival than FEV1.[3]  Our findings suggests that the observed association between 210 
low FEV1, obstruction and increased risk of CVD is unlikely to be causal. In healthy 211 



































unknown underlying biological mechanism linking lung function and cardiovascular disease 213 
may be specific to FVC reduction.  214 
Finding modifiable risk factors for CAD is important, however the majority of therapies 215 
designed to improve lung function (such as inhaled bronchodilators) have a temporary and 216 
limited impact on FVC and so are unlikely to be sufficient to modify cardiovascular risk. 217 
Available treatments which do target decline in FVC are for specific and rare lung disease 218 
such as pulmonary fibrosis.[29]  219 
There are a number of strengths to our study, first it utilises large numbers of instrumental 220 
variables, far more than were available in previous MR studies.[30] Second we used a huge 221 
exposure sample populations and multiple robust methods and adhered to rigorous proposed 222 
STROBE guidelines for MR papers.[31]. By using MR we accounted for unmeasured 223 
confounding and reverse causation, problems typical of conventional observational 224 
epidemiology and establish causality by the use of randomly assigned genetic instrumental 225 
variables.[13, 32, 33] In addition, our study benefited from using MVMR to condition for 226 
these covariates avoiding collider bias that could have contributed to the weak evidence found 227 
in our preliminary analysis using the Shrine et al GWAS.[19] MVMR estimates the direct, 228 
rather than total effect of an exposure allowing us to show that much of the effect of FEV1 on 229 
CAD risk was due to pleiotropic SNPs affecting FEV1 via height (an established determinant 230 
of cardiovascular risk). Finally, this is the first study to use SNPs for FEV1/FVC <0·7 ratio. 231 
MR has assumptions and is vulnerable to certain biases if not used properly. The sensitivity 232 
analysis using plots, MR Egger, weighted median and mode did not indicate any violation of 233 
assumptions. The use of Steiger filtering reduces the risk of reverse causality.  234 
Limitations 235 
Our exposure GWAS and the MEGASTROKE used only those of European heritage. The 236 




European ancestral populations in the Shrine GWAS have been shown to have a smaller 238 
effect in non-European populations.[19] As our own UKBiobank GWASs used a high 239 
proportion of the same sample examining similar traits, it is likely that in a non-European 240 
population the effects would be smaller. We did not have access to another sample population 241 
to estimate the effects of SNPs discovered in our GWAS. As our SNPs were discovered and 242 
effects estimated in the same population, the effects could have been over estimated due to 243 
“Winner’s Curse” phenomena.[34] There was a reduction in number of instruments available 244 
for analysis following LD-clumping, removal of duplicates, and extraction from exposure and 245 
outcome GWAS. This reduces the strength of the instruments which may have reduced the 246 
power to show an effect of FEV1 or FEV1/FVC <0.7 ratio. In our MVMR analysis we used 247 
FEV1/FVC <0.7 ratio as an exposure because this is a commonly used, threshold of 248 
obstructive lung function. Using FEV1/FVC ratio as a continuous trait has inherent issues in 249 
MR analysis. High FEV1/FVC ratio is a sign of restriction and low FEV1/FVC ratio defines 250 
airflow obstruction, both of which are pathological states that could affect cardiovascular 251 
disease, making interpretation of the continuous variable challenging. Most MR analysis 252 
assumes a linear effect, which would be violated when using FEV1/FVC as a continuous trait. 253 
Dichotomization of continuous traits in MR studies can make interpretation of the causal 254 
estimate less reliable, but MR can still be a valid test of the causal null hypothesis for a binary 255 
exposure.[35] An assumption of MR is that SNPs only affect the outcome via the exposure. 256 
To ensure that our SNPs were not affecting our outcomes via amount smoked we checked to 257 
see if any of our lung function SNPs are found in the 15q25 locus.[36] In the MVMR analysis 258 
for FEV1 only one SNP (rs72736802) is from the locus, none from the FVC analysis. 259 
Therefore, we do not think this will affect our results. Lung function is a complex trait and 260 
SNPs affect LF via differing pathological processes.[19] The differing processes may vary in 261 




heterogeneity. It is possible our study was limited by the number of ischaemic stroke cases in 263 
the outcome population. If there is a causal effect of lung function on ischaemic stroke, it is 264 
likely to only occur with large changes in lung function as seen with CAD.  265 
Implications 266 
There are several important implications of our findings, first is that it is Forced Vital 267 
Capacity not obstructive lung function that is causally associated with coronary artery disease. 268 
This suggests that we should focus our attention on understanding the mechanisms by which 269 
FVC causes CAD. Second given, there are limited FVC specific therapies, it is most likely 270 
that future interventions to improve CAD outcomes through modifying FVC are most likely 271 
to be achieved through environmental/ behavioural public health interventions designed to 272 
achieve optimal lung development and preventing lung function decline. Third, FVC is a 273 
widely and routinely collected clinical measure (spirometry), this study supports the call for 274 
FVC measurements to be evaluated as part of cardiovascular prognostication / secondary 275 
prevention risk assessments.  276 
It remains uncertain if lung function has a causal effect on the risk of ischaemic stroke. 277 
Although oOur MVMR models show very little weak evidence that reduced lung function 278 
increases the risk of ischaemic stroke, the evidence is weak. Larger outcome sample sizes and 279 
more SNPs may become available as genetic consortia grow which could provide more 280 
conclusive results. Future studies are needed to determine the mechanism by which FVC 281 
causes increased coronary artery disease. 282 
 283 
Conclusions 284 
There is strong evidence that reduced Forced Vital Capacity (FVC) is independently and 285 
causally associated with Coronary Artery Disease. Although the mechanism remains unclear, 286 




studies are needed to test whether interventions to improve or maintain FVC may also modify 288 
cardiovascular risk. FEV1 and Obstructive lung function do not appear to cause increased 289 
cardiovascular events, confounding and collider bias may explain previous observational and 290 
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